Monocyte chemoattractant protein-1 as a marker of systemic lupus erythematosus: an observational study

Živković, Vesna; Cvetković, Tatjana; Mitić, Branka; Stamenković, Bojana; Stojanović, Simona; Radovanović-Dinić, Biljana; Jurišić, Vladimir

doi:10.1007/s00296-017-3888-x

Cited by 31 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing MCP-1 increased VT and MCS, which contradicts the data on the disease activity in SLE, where the serum, cerebrospinal and urinary MCP-1 levels were increased with disease exacerbation; and MCP-1 was also shown to be associated with fatigue and depression in SLE; while simultaneously beingnegatively associated with all SF-36 items, (all, p < 0.01) [4]. Our results were similar to other studies which showed that the MCP-1 levels remain elevated after a long-term immunosuppression, even when the disease activity had subsided [44,45,46]. More generally, MCP-1 levels have been shown to be equivalent between women with and without Exhaustion Disorders, anxiety or depression [47]; and MCP-1 is important for combating bacterial infections [48].…”

Section: Discussionsupporting

confidence: 89%

The Impact of Cytokines on the Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus

Raymond

Eilertsen

Shanmugakumar

et al. 2019

JCM

View full text Add to dashboard Cite

Introduction: Systemic lupus erythematosus (SLE) reduces the health-related quality of life (HRQoL), even during periods of disease quiescence. We investigated whether subclinical inflammation as reflected by cytokine levels is linked with reduced HRQoL. Methods: A cross-sectional study of SLE patients (n = 52, mean age 47.3, 86.5% female) who completed a Short Form Health Survey-36 (SF-36) questionnaire. The clinical and demographic data, scores for the disease activity (SLEDAI-2K), organ damage (SDI), and laboratory data were collected simultaneously. The autoantibody and cytokine levels (IFN-γ, IL-1β, IL-4, IL-6, IL-10, IL-12, IL-17, BAFF, TNF-α, TGF-β1, MIP-1α, MIP-1β and MCP-1 (levels in pg/mL) were quantified by sandwich ELISA. The comparisons and associations were assessed non-parametrically, and a multiple regression determined the effect sizes (ES) of the variables on the SF-36 domain and summary scores. Results: The SF-36 summary and domain scores for SLE patients were significantly (20–40%) lower than in a comparable control group, with the exception of the Mental Health scores (p = 0.06). SLE patients had a normal body mass index (BMI) (median, 24.2 kg/m2), a high rate of smoking (69.2%), and usage of social security benefits (90.4%). TGF-β1 (ES 0.06), IL-12 (ES −0.11), IFN-γ (ES 0.07) and MCP-1 (ES 0.06) influenced the SF-36 domain scores; and MCP-1 (ES 0.04) influenced the Mental Health Summary Score (MCS). Obvious manifestations, including patient visual analogue scale (VAS) (ES −2.84 to −6.29), alopecia (ES −14.89), malar rash (ES −14.26), and analgesic requirement (ES −19.38), independently influenced the SF-36 items; however, the SF-36 scores were not reflected by the physician VAS or disease activity (SLEDAI-2K). Conclusions: Cytokines had a minimal impact on HRQoL in SLE patients, especially compared to visible skin manifestations, central nervous system (CNS) damage, and pain. Better tools are needed to capture HRQoL in measures of disease activity.

show abstract

Section: Discussionsupporting

confidence: 89%

The Impact of Cytokines on the Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus

Raymond

Eilertsen

Shanmugakumar

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Despite the inconsistent results, these proinflammatory cytokines/chemokines have emerged as candidate biomarkers to show disease activity. 10–19 Only a handful of studies have involved patients without SLE. 10,16,20…”

Section: Introductionmentioning

confidence: 99%

Serum and urine TNF-like weak inducer of apoptosis, monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus

Mirioglu

Çınar

Yazıcı

et al. 2020

Lupus

View full text Add to dashboard Cite

Objectives TNF-like weak inducer of apoptosis (TWEAK), monocyte chemoattractant protein-1 (MCP-1) and neutrophil gelatinase-associated lipocalin (NGAL) are proinflammatory cytokines/chemokines that are considered as potential biomarkers reflecting disease activity in systemic lupus erythematosus (SLE). In this study, we aimed to investigate the association of serum (s) and urine (u) levels of TWEAK, MCP-1 and NGAL with disease activity in both renal and extra-renal SLE. Methods Thirty active patients with SLE (15 renal and 15 extra-renal) were recruited. Thirty-one inactive patients with SLE (16 renal and 15 extra-renal), 14 patients with ANCA-associated vasculitis (AAV) all of whom had active renal involvement and 20 healthy volunteers were selected as control groups. Serum and urine levels of TWEAK, MCP-1 and NGAL were tested using ELISA. Results Serum and urine levels of TWEAK and NGAL were significantly higher in the active SLE group compared to the inactive SLE group (sTWEAK p = 0.005; uTWEAK p = 0.026; sNGAL p < 0.001; uNGAL p = 0.002), whilst no significant differences regarding serum and urine MCP-1 levels were observed ( p = 0.189 and p = 0.106, respectively). uTWEAK ( p = 0.237), sMCP-1 ( p = 0.141), uMCP-1 ( p = 0.206), sNGAL ( p = 0.419) and uNGAL ( p = 0.443) levels did not differ between patients with active renal and extra-renal SLE. Serum TWEAK was higher in patients with active renal SLE ( p = 0.006). There were no differences between active renal SLE and active renal AAV. Levels of all biomarkers were correlated with the SLE Disease Activity Index. Conclusion sTWEAK, uTWEAK, sNGAL and uNGAL are biomarkers showing disease activity in SLE. However, our results implicate that these biomarkers may not be specific for SLE, and can be elevated in patients with active renal involvement of AAV.

show abstract

“…Even if it is produced by many cell types, it is mainly expressed by activated monocytes/macrophages, T cells, and natural killer cells and takes part in leukocyte infiltration to the kidney [26]. This and the observation that its antagonist can ameliorate the induction and progression of LN in transgenic mouse model [27], make it one of the most used biomarkers when considering LN. As shown in online suppl.…”

Section: Resultsmentioning

confidence: 99%

Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Introduction: While renal biopsy remains the gold standard for diagnosing lupus nephritis (LN), the prognostic and diagnostic role of non-invasive biomarkers for LN is currently debated. Methods: Available studies published in last 5 years (2015–2020) assessing the diagnostic and prognostic value of urinary and/or serological biomarkers in subjects with LN were analyzed in this systematic review. Results: Eighty-five studies were included (comprehending 13,496 patients with systemic lupus erythematosus [SLE], 8,872 LN, 487 pediatric LN, 3,977 SLE but no LN, 160 pediatric SLE but no LN and 7,679 controls). Most of the studies were cross-sectional (62; 73%), while 14 (17%) were prospective. In sixty studies (71%), the diagnosis of LN was biopsy-confirmed. Forty-four out of 85 (52%) investigated only serological biomarkers, 29 studies (34%) tested their population only with urinary biomarkers, and 12 (14%) investigated the presence of both. Outcome measures to assess the clinical utility of the analyzed biomarkers were heterogeneous, including up to 21 different activity scores, with the SLEDAI (in 60%) being the most used. Despite some heterogeneity, promising results have been shown for biomarkers such as urinary monocyte chemoattractant protein, urinary adiponectin, and urinary vascular cell adhesion protein 1. Discussion/Conclusion: While serum and urine biomarkers have the potential to improve diagnostic and prognostic pathways in patients with LN, the vast heterogeneity across studies severely limits their applicability in current clinical practice. With the kidney biopsy still representing the gold standard, future efforts should focus on harmonizing study inclusion criteria and outcomes, particularly in clinical trials, in order to improve comparability and facilitate the implementations of available biomarkers into the daily practice.

show abstract

Monocyte chemoattractant protein-1 as a marker of systemic lupus erythematosus: an observational study

Cited by 31 publications

References 33 publications

The Impact of Cytokines on the Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus

The Impact of Cytokines on the Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus

Serum and urine TNF-like weak inducer of apoptosis, monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus

Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review

Contact Info

Product

Resources

About